All In Biotech

Drug Trial Radar · NCT07082192

A Study to Evaluate the Efficacy and Safety of Different Doses of CB03-154 in Adult Patients With Amyotrophic Lateral Sclerosis (ALS)

A Multicenter, Randomized, Double-blind, Placebo-controlled Phase II/III Adaptive Clinical Study and Open-label Extension Study to Evaluate the Efficacy and Safety of Different Doses of CB03-154 in Adult Patients With Amyotrophic Lateral Sclerosis (ALS)

Last checked: Nov 19, 2026Latest source record: Sep 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 240 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

240

Planned (sponsor's estimate)

Start

Oct 30, 2025

Primary completion

Sep 30, 2027

Study completion Oct 2027

Sponsor

Sponsor type
Industry
First posted
Jul 24, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to learn if drug CB03-154 works to treat ALS in adults. It will also learn about the safety of drug CB03-154. The main questions it aims to answer are: * Does drug CB03-154 have an effect on delaying disease progression, improving function, and prolonging survival in adult ALS patients? * What medical problems do patients have when taking drug CB03-154? Researchers will compare drug CB03-154 to a placebo (a look-alike substance that contains no drug) to see if drug CB03-154 works to treat ALS. Participants (adult ALS patients) will: * Take drug CB03-154 or a placebo every day for 39 weeks (an additional 39 weeks would be required if entering the open-label extension phase). * Visit the clinic approximately every 2-3 months for checkups and tests, and there is also telephone follow-up in between. * Keep a diary of daily medication (CB03-154 or other concomitant medications), and if there are any unplanned medications, the reason (disease or symptoms) also need be recorded.

Conditions

  • ALS (Amyotrophic Lateral Sclerosis)

Interventions

  • Test drug CB03-154 5mg groupDrug

    One CB03-154 tablet (5mg/tablet) once daily.

  • Test drug CB03-154 10mg groupDrug

    Two CB03-154 tablets (5mg/tablet) once daily.

  • Test drug CB03-154 15mg groupDrug

    Three CB03-154 tablets (5mg/tablet) once daily.

  • Placebo GroupDrug

    Three Placebo tablets once daily.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Changes from Baseline to Week 39 in ALS Functional Rating Scale-Revised (ALSFRS-R).(Part A) Changes from Baseline to Week 78 in ALS Functional Rating Scale-Revised (ALSFRS-R).(Part B)Time frame: From baseline to the entire period of double-blind period, assessed up to 39 weeks. (Part A) From baseline to the entire period of open-label extension, assessed up to 78 weeks. (Part B)

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Peking University Third Hospital

    Beijing, Beijing Municipality, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.